The key point: BPC-157 should only be considered with guidance from a licensed provider who understands peptide therapy, safety, and current regulations
Research Background BPC-157 has demonstrated cytoprotective and healing properties in numerous animal studies
The treatment was too weak, wore off in 6 weeks instead of 3 to 4 months, or never worked at all
N Pedersen, M Schmitt, E Rnne, M I Nicoletti, G Hyer-Hansen, M Conese, R Giavazzi, K Dano, W Kuhn, F Jnicke Bradykinin stimulates diverse functions in endothelial cells including the release of endothelium-derived relaxing factor (EDRF)
This might include modifying doses, changing administration timing, or adding complementary treatments